New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the effectiveness of the Marseille’s research network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and innovative approaches in cancer immunotherapy, based on these three pillars. New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams’ dynamism and local potential.
Diagnostic in immuno-oncology is an innovative field combining the latest discoveries in immunology and new imaging technologies, such as digital pathology.
Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
Thanks to this unprecedented alliance of researchers, clinicians, technological platforms and industrials we should be able to quickly do much better